faculty portrait if available
Ronald Hill
Associate Professor
School Basic Pharm & Toxicol Sci
PHAR 310
318-342-1706
ULM logo

Ronald A Hill, PhD
Associate Professor, Pharmacy

Education

Ph D

1991, Pharmacy
The Ohio State University

Biographical Sketch

Dr. Hill earned a B.S.Chem. at U. of Michigan, Ann Arbor, With Distinction and Highest Honors in Chemistry (Honors Thesis with Peter A. S. Smith).  He then spent 4.3 years at The Upjohn Company working in product-end R&D in the areas of biopharmaceutics and pharmaceutical analysis relating to formulations development and quality control.  Subsequently, he returned to school, earning his Ph.D. in Pharmacy (organic medicinal and computational chemistry) at The Ohio State U., mentored in his research by Prof. Duane Miller and also Dr. Jan Labanowski (Ohio Supercomputer Center), as well as several outstanding neuropharmacology faculty members (including Profs. Lane Wallace and Norman Uretsky).  During his subsequent academic career, his research was funded at various times by the NIH and American Heart Association.  His educating duties at the Ph.D. and Pharm.D. levels have been extensive, and carried out with the underlying hope that understandings of the molecular design/engineering of medicinals and of the science behind their actions will be intelligently, artfully, and judiciously acted on in clinical practice. 

Research Interests

Over a pharmaceutical sciences career now spanning almost 38 years, Dr./Prof. Hill has overarchingly aimed--by collaborator-driven opportunity as much as by intentional navigation--at becoming a high-level generalist in relating the chemistry of biologically active molecules to their interactions with, and actions on, humans and their hosted organisms (normal microbiome, microbial pathogens, parasites). Dr. Hill's own research has generally pertained to the central nervous system (CNS/brain), but extended into other areas, while guided strongly by an intent to continually gain ever deeper and broader acumen in medicinal and pharmaceutical chemistry, biopharmaceutics (molecular and systemic), pharmacokinetics, delivery systems, biochemical/molecular pharmacology, and molecular toxicology--and in general, the totality of the science behind molecular therapeutics design and the successful bridging of discovery at its earliest stages to eventual clinical applications.  Consistent with Dr. Hill's strong belief in the vital importance and prospectively great educational impact of dedicated teacher-researchers, his scholarly and research emphases accord strongly with his contributions to educating Pharm.D. graduates who are foundationally prepared to make high-value contributions to patient care, as well as Ph.D. students who begin as emerging scientists well grounded in various areas of discovery, design, and preclinical testing of pharmacologically active molecules.  Dr. Hill's current research collaborations pertain to cancer and neurodegenerative conditions.  

Recent Publications

Roy, T., Boateng, S. T., Banang-Mbeumi, S., Singh, P. K., Basnet, P., Chamcheu, R. N., Ladu, F., Chauvin, I., Spiegelman, V. S., Hill, R. A., Kousoulas, K. G., Nagalo, B. M., Walker, A. L., Fotie, J., Murru, S., Sechi, M., Chamcheu, J. (2021). Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation. (pp. 106858). Data in Brief.
Roy, T., Boateng, S. T., Banang-Mbeumi, S., Singh, P. K., Basnet, P., Chamcheu, R. N., Ladu, F., Chauvin, I., Spiegelman, V. S., Hill, R. A., Kousoulas, K. G., Nagalo, B. M., Walker, A. L., Fotie, J., Murru, S., Sechi, M., Chamcheu, J. C. (2021). Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers (pp. 104595). Bioorganic Chemistry.
Hill, R. A., Liu, Z., Liu, Y. (2020). Small Ceramide Tames Big p53 Mutant Beast (Editorial) (pp. 3418-3419). Oncotarget.
Roy, K. R., Uddin, M. B., Roy, S. C., Hill, R. A., Marshall, J., Li, Y., Chamcheu, J. C., Lu, H., Liu, Y. (2020). Gb3-cSrc complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β-catenin activated RNA methylation. (pp. 653-667). FASEB BioAdvances.
Khiste, S. K., Liu, Z., Roy, K. R., Uddin, M., Hosain, S. B., Gu, X., Nazzal, S., Hill, R. A., Liu, Y. (2020). Ceramide-rubusoside nanomicelles, a potential therapeutic approach to target cancers carrying p53 missense mutations. (pp. 564-574). Philadelphia, PA: Molecular Cancer Therapeutics.
Hosain, S. B., Khiste, S. K., Uddin, M. B., Vorubindi, V., Ingram, C., Zhang, S., Hill, R. A., Gu, X., Liu, Y. A. (2016). Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells. (pp. 60575-60592). Orchard Park, NY: Oncotarget.
Ebrahim, H. Y., Akl, M. R., Elsayed, H. E., Hill, R. A., El Sayed, K. A. (2017). Usnic Acid Benzylidene Analogues as Potent Mechanistic Target of Rapamycin Inhibitors for the Control of Breast Malignancies (pp. 932-952). Washington, DC: Journal of Natural Products.
Khiste, S. K., Hosain, S. B., Dong, Y., Uddin, M. B., Roy, K. R., Hill, R. A., Liu, Z., Liu, Y. (2017). Incorporation of Fluorescence Ceramide-Based HPLC Assay for Rapidly and Efficiently Assessing Glucosylceramide Synthase In Vivo (pp. 2976). Scientific Reports.
Uddin, M. B., Roy, K. R., Hosain, S. B., Khiste, S. K., Hill, R. A., Jois, S. D., Zhao, Y., Tackett, A. J., Liu, Y., Hill, R. A. (2019). An N6-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. (pp. 134-145). Kansas City, KS: Biochemical Pharmacology.
Siddique, A. B., Ayoub, N. M., Tajmim, A., Meyer, S. A., Hill, R. A., El Sayed, K. A. (2019). (-)-Oleocanthal Prevents Breast Cancer Locoregional Recurrence After Primary Tumor Surgical Excision and Neoadjuvant Targeted Therapy in Orthotopic Nude Mouse Models. (pp. E637). Basel: Cancers (Basel).
Hosain, S. B., Hill, R. A., Liu, Y. (2013). Trends in Stem cell Proliferation and Cancer Research (pp. 167-191). Springer.
Liu, Y., Hill, R. A., Li, Y. (2013). Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance (pp. 59-89). Academic Press: Advances in cancer research.
Hisham, Q., Alaa, A. H., Hill, R. A., Khalil, A. (2012). Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease (pp. 151-65). Journal of Alzheimer’s Disease.
Satyanarayana-Jois, S., Hill, R. A. (2011). Medicinal chemistry for 2020 (pp. 1765-1786). Future Medicinal Chemistry/Future Science Group.
Hill, R. A., Khanfar, M. A., Khalil, A., El Sayed, K. (2010). Discovery of Novel GSK-3β Inhibitors with Potent in Vitro and in Vivo Activities and Excellent Brain Permeability Using Combined Ligand- and Structure-Based Virtual Screening (pp. 8534-8545). ACS Journals: Journal of Medicinal Chemistry.
Hill, R. A. (2010). Chapter 20: Hormone-Related Disorders–Nonsteroidal Therapies. In: Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry. John H. Block, John M. Beale, Jr., Eds. (pp. 666–704). Philadelphia: Wolters Kluwer Health | Lippincott Williams & Williams.
L., Z. O., M., F. V., N., N. T., Hill, R. A., R., M. D., D. V., H. G., S., A. M. (2009). Identification of the major human hepatic and placental enzymes responsible for the metabolism of glyburide (pp. 1483-1490.). Biochemical Pharmacology.
Devarakonda, B., Otto, D. P., Judefeind, A., Hill, R. A., Devilliers, M. M. (2007). Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. (pp. 142–153). International Journal of Pharmaceutics.
Zharikova, O. L., Ravindran, S., Nanovskaya, T. N., Hill, R. A., Hankins, G. D., Ahmed, M. S. (2007). Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon. (pp. 2012–2019). Biochemical Pharmacology.
Chilakapati, J., Korrapati, M. C., Shankar, K., Hill, R. A., Warbritton, A., Latendresse, J. R., Mehendale, H. M. (2007). Role of CYP2E1 and saturation kinetics in the bioactivation of thioacetamide: effects of diet restriction and phenobarbital. (pp. 72–84). Toxicology and Applied Pharmacology.
Chilakapati, J., Korrapati, M. C., Hill, R. A., Warbritton, A., Latendresse, J. R., Mehendale, H. M. (2007). Role of thioacetamide sulfoxide in saturation of toxicokinetics of thioacetamide. (pp. 105–116). Toxicology.
Ravindran, S., Zharikova, O. L., Hill, R. A., Nanovskaya, T. N., Hankins, G. D., Ahmed, M. S. (2006). Identification of Glyburide Metabolites formed by Hepatic and Placental Microsomes of Humans and Baboons. (pp. 1730–1737). Biochemical Pharmacology.
Schulte, M. K., Hill, R. A., Bikádi, Z., Maksay, G., Parihar, H. S., Joshi, P., Suryanarayanan, A. (2006). The structural basis of ligand interactions in the 5-HT3 receptor binding site. (pp. 127–154). In Biological and Biophysical Aspects of Ligand-Gated Ion Channel Receptor Superfamilies. Arias, Hugo R., editor. Research Signpost Press.
Devarakonda, B., Hill, R. A., Liebenberg, W., Brits, M., Devilliers, M. M. (2005). Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. (pp. 193–209). International Journal of Pharmaceutics.
Chilakapati, J., Shankar, K., Korrapati, M. C., Hill, R. A., Mehendale, H. M. (2005). Saturation Toxicokinetics of Thioacetamide: Role in Development of Liver Injury. (pp. 1877–1885). Drug Metabolism and Disposition.
Devarakonda, B., Hill, R. A., Devilliers, M. M. (2004). The Effect of PAMAM Dendrimer Generation Size and Surface Functional Group on the Aqueous Solubility of Nifedipine. (pp. 133–140). International Journal of Pharmaceutics.
Hill, R. A., Rudra, S., Peng, B., Roane, D., Bounds, J. K., Zhang, Y., Adloo, A. A., Lu, T. (2003). Hydroxyl-Substituted Sulfonylureas as Potent Inhibitors of Specific [3H]Glyburide Binding to Rat Brain Synaptosomes. (pp. 2099-2113). Bioorganic and Medicinal Chemistry.

Awards & Honors

May 2013 P3 Teacher of the Year.

May 2013 P1 Teacher of the Year.

December 2008 Selected to serve on Cosmetic Ingredient Review Expert Panel.

May 2005 ULM Basic Pharmaceutical Sciences Teacher of the Year – 2004-2005.

April 1998 Honor Society of Phi Kappa Phi inductee.

April 1995 Rho Chi Teacher of the Year Award.

April 1992 Favorite Teacher Award.

February 1991 Predoctoral Fellow Research Presentation Travel Grant.

May 1988 Fellow of the American Foundation for Pharmaceutical Education – 1988–1991.

May 1987 Honorable Mention.

April 1986 University Fellow.

May 1982 Highest Honors in Chemistry.

Courses Taught

PHAR 4009Medicinal Chemistry II, 3 course(s)

PHAR 4010Medicinal Chemistry III, 4 course(s)

PHAR 5013PHARMACOKINETICS, 4 course(s)

PHAR 5051Directed Study, 2 course(s)

PHAR 5069CONCEPTS IN DRUG DESIGN, 7 course(s)

PHAR 5070MEDICINAL CHEM DRUG DISCOVERY, 5 course(s)

PHAR 5137MEDICINAL CHEMISTRY SURVEY, 1 course(s)

PHAR 5139MOLEC THEOR FNDTNS, 8 course(s)

PHRD 4002PRINCIPLES OF DRUG ACTION I, 12 course(s)

PHRD 4008PHARMACEUTICS I, 3 course(s)

PHRD 4027PRINCIPLES OF DRUG ACTION II, 8 course(s)

PHRD 4029PHARMACEUTICS II, 2 course(s)

PHRD 4056BIOPHARM & KINETICS, 5 course(s)

PHRD 4058NEUROLOGY & PSYCHIATRY MODULE, 4 course(s)

PHRD 4074ENDOCRINE MODULE, 4 course(s)

PHRD 4083GASTRO NUTRITION & HEPTIC MOD, 5 course(s)

PHRD 4093THERAPEUTICS IV, 3 course(s)

PHRD 5010CARDIOVASCULAR MODULE, 6 course(s)

PHRD 5022THERAPEUTICS VI, 2 course(s)

PHRD 5027BONE AND JOINT MODULE, 7 course(s)

PHRD 5031RESPIRATORY MODULE, 3 course(s)

PHRD 5033RENAL/UROLOGY MODULE, 5 course(s)

PHRD 5037EYES, EARS, THROAT & DERM MOD, 7 course(s)

PHRD 5039THERAPEUTICS VII, 2 course(s)